1. Home
  2. ITRM
  3. ITRM News

Latest Iterum Therapeutics plc (ITRM) News on December 18, 2024

ITRM

MT Newswires

a month ago

Iterum Therapeutics Shares Rise After Regaining Compliance With Nasdaq's Listing Rules

Iterum Therapeutics Regains Full Nasdaq Compliance
ITRM

GlobeNewswire

a month ago

Iterum Therapeutics Regains Full Nasdaq Compliance

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...
ITRM

GuruFocus.com

a month ago

Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...

Iterum Therapeutics Reports Third Quarter 2024 Financial Results
ITRM

GlobeNewswire

a month ago

Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
ITRM

GlobeNewswire

a month ago

Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships
ITRM

Benzinga

2 months ago

FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships

FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment
ITRM

Pharmaceutical Technology

2 months ago

FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
ITRM

PR Newswire

2 months ago

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

ITRM

MT Newswires

2 months ago

Top Midday Gainers

ITRM

MT Newswires

2 months ago

Sector Update: Health Care Stocks Decline Friday Afternoon

ITRM

MT Newswires

2 months ago

Iterum Therapeutics Shares Rise as FDA Approves Orlynvah as Treatment for Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
ITRM

GlobeNewswire

2 months ago

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics to Present Data at IDWeek 2024
ITRM

GlobeNewswire

2 months ago

Iterum Therapeutics to Present Data at IDWeek 2024

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
ITRM

GlobeNewswire

2 months ago

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit

Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts
ITRM

Pharmaceutical Technology

3 months ago

Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts

ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
ITRM

Zacks

3 months ago

ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down

Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
ITRM

GlobeNewswire

3 months ago

Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women

Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
ITRM

GlobeNewswire

3 months ago

Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference

When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable?
ITRM

Simply Wall St.

4 months ago

When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable?

Iterum Therapeutics Reports Second Quarter 2024 Financial Results
ITRM

GlobeNewswire

4 months ago

Iterum Therapeutics Reports Second Quarter 2024 Financial Results

Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
ITRM

GlobeNewswire

4 months ago

Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Iterum Therapeutics Announces Expiration and Results of Rights Offering
ITRM

GlobeNewswire

4 months ago

Iterum Therapeutics Announces Expiration and Results of Rights Offering

Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
ITRM

GlobeNewswire

5 months ago

Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem

ITRM

MT Newswires

5 months ago

Iterum Therapeutics Starts Rights Offering

Iterum Therapeutics Commences Rights Offering
ITRM

GlobeNewswire

5 months ago

Iterum Therapeutics Commences Rights Offering

ITRM

MT Newswires

6 months ago

Iterum Therapeutics' New Drug Application for Sulopenem Referred to FDA Advisory Committee

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
ITRM

GlobeNewswire

6 months ago

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

Iterum Therapeutics to Present Data at ASM Microbe 2024
ITRM

GlobeNewswire

6 months ago

Iterum Therapeutics to Present Data at ASM Microbe 2024

Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
ITRM

GlobeNewswire

7 months ago

Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

ITRM

Thomson Reuters StreetEvents

7 months ago

Q1 2024 Iterum Therapeutics PLC Earnings Call

Iterum Therapeutics Reports First Quarter 2024 Financial Results
ITRM

GlobeNewswire

7 months ago

Iterum Therapeutics Reports First Quarter 2024 Financial Results

Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
ITRM

GlobeNewswire

7 months ago

Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
ITRM

GlobeNewswire

8 months ago

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript
ITRM

Insider Monkey

9 months ago

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript

ITRM

Thomson Reuters StreetEvents

9 months ago

Q4 2023 Iterum Therapeutics PLC Earnings Call

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
ITRM

GlobeNewswire

9 months ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
ITRM

GlobeNewswire

9 months ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
ITRM

GlobeNewswire

9 months ago

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
ITRM

Zacks

9 months ago

Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up

Iterum Therapeutics Provides Business Update
ITRM

GlobeNewswire

9 months ago

Iterum Therapeutics Provides Business Update

Steven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLC
ITRM

GuruFocus.com

a year ago

Steven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLC

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
ITRM

PR Newswire

a year ago

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Home Federal Bancorp of Louisiana Second Quarter 2024 Earnings: EPS: US$0.33 (vs US$0.57 in 2Q 2023)
ITRM

Simply Wall St.

a year ago

Home Federal Bancorp of Louisiana Second Quarter 2024 Earnings: EPS: US$0.33 (vs US$0.57 in 2Q 2023)

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
ITRM

GlobeNewswire

a year ago

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
ITRM

GlobeNewswire

a year ago

Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
ITRM

GlobeNewswire

a year ago

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

D-Wave Names Kirstjen Nielsen, Former Secretary of Homeland Security, to Board of Directors
ITRM

Business Wire

a year ago

D-Wave Names Kirstjen Nielsen, Former Secretary of Homeland Security, to Board of Directors

Contrarian Kings: 3 Unloved Stocks That Could Be the Next Market Darlings
ITRM

InvestorPlace

a year ago

Contrarian Kings: 3 Unloved Stocks That Could Be the Next Market Darlings

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
ITRM

PR Newswire

a year ago

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India
ITRM

Business Wire

a year ago

Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ITRM

PR Newswire

a year ago

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™
ITRM

Business Wire

a year ago

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™

American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
ITRM

Business Wire

a year ago

American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event

MEDIROM Healthcare Technologies First Half 2023 Earnings: JP¥72.72 loss per share (vs JP¥37.18 loss in 1H 2022)
ITRM

Simply Wall St.

a year ago

MEDIROM Healthcare Technologies First Half 2023 Earnings: JP¥72.72 loss per share (vs JP¥37.18 loss in 1H 2022)

Here's Why We Think North European Oil Royalty Trust (NYSE:NRT) Is Well Worth Watching
ITRM

Simply Wall St.

a year ago

Here's Why We Think North European Oil Royalty Trust (NYSE:NRT) Is Well Worth Watching

11 Popular Penny Stocks on Robinhood
ITRM

Insider Monkey

a year ago

11 Popular Penny Stocks on Robinhood

Lument Finance Trust, Inc. Declares Quarterly Cash Dividends for its Common and Preferred Stock
ITRM

PR Newswire

a year ago

Lument Finance Trust, Inc. Declares Quarterly Cash Dividends for its Common and Preferred Stock

Westport Joins Forces with Transportation and Energy Partners to Demonstrate ICE Hydrogen-Powered Transport in Sweden
ITRM

CNW Group

a year ago

Westport Joins Forces with Transportation and Energy Partners to Demonstrate ICE Hydrogen-Powered Transport in Sweden

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)
ITRM

GlobeNewswire

a year ago

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Why Is Westport (WPRT) Up 17.5% Since Last Earnings Report?
ITRM

Zacks

a year ago

Why Is Westport (WPRT) Up 17.5% Since Last Earnings Report?

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
ITRM

GlobeNewswire

a year ago

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

Monroe Capital Corporation Announces Fourth Quarter Distribution of $0.25 Per Share
ITRM

GlobeNewswire

a year ago

Monroe Capital Corporation Announces Fourth Quarter Distribution of $0.25 Per Share

3 Top-Rated Cannabis Stocks That Analysts Are Loving Now
ITRM

InvestorPlace

a year ago

3 Top-Rated Cannabis Stocks That Analysts Are Loving Now

Cool Company Ltd. Q3 2023 Business Update
ITRM

Business Wire

a year ago

Cool Company Ltd. Q3 2023 Business Update

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
ITRM

GlobeNewswire

a year ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Sypris Solutions, Inc. (NASDAQ:SYPR) Q3 2023 Earnings Call Transcript
ITRM

Insider Monkey

a year ago

Sypris Solutions, Inc. (NASDAQ:SYPR) Q3 2023 Earnings Call Transcript

ITRM

Associated Press Finance

a year ago

North European Oil Royalty: Fiscal Q4 Earnings Snapshot

ITRM

PR Newswire

a year ago

NORTH EUROPEAN OIL ROYALTY TRUST ANNOUNCES THE NET INCOME FOR THE FOURTH QUARTER OF FISCAL 2023

B. Riley Financial, Inc. Bolsters Position in Babcock & Wilcox Enterprises Inc
ITRM

GuruFocus.com

a year ago

B. Riley Financial, Inc. Bolsters Position in Babcock & Wilcox Enterprises Inc

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript
ITRM

Insider Monkey

a year ago

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript

Sypris Reports Third Quarter Results
ITRM

Business Wire

a year ago

Sypris Reports Third Quarter Results

ITRM

Thomson Reuters StreetEvents

a year ago

Q3 2023 Iterum Therapeutics PLC Earnings Call

Iterum Therapeutics Reports Third Quarter 2023 Financial Results
ITRM

GlobeNewswire

a year ago

Iterum Therapeutics Reports Third Quarter 2023 Financial Results

ATA Creativity Global Reports 2023 Third Quarter Financial Results
ITRM

GlobeNewswire

a year ago

ATA Creativity Global Reports 2023 Third Quarter Financial Results

Here's What We Like About Arko's (NASDAQ:ARKO) Upcoming Dividend
ITRM

Simply Wall St.

a year ago

Here's What We Like About Arko's (NASDAQ:ARKO) Upcoming Dividend

Synchronoss Technologies, Inc. (NASDAQ:SNCR) Q3 2023 Earnings Call Transcript
ITRM

Insider Monkey

a year ago

Synchronoss Technologies, Inc. (NASDAQ:SNCR) Q3 2023 Earnings Call Transcript

Tortoise Announces Final Results of Tender Offers for its Closed-End Funds
ITRM

ACCESSWIRE

a year ago

Tortoise Announces Final Results of Tender Offers for its Closed-End Funds

Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023
ITRM

GlobeNewswire

a year ago

Iterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023

ARKO Corp Reports Decrease in Net Income and Adjusted EBITDA in Q3 2023
ITRM

GuruFocus.com

a year ago

ARKO Corp Reports Decrease in Net Income and Adjusted EBITDA in Q3 2023

ARKO Corp. Reports Third Quarter 2023 Results
ITRM

GlobeNewswire

a year ago

ARKO Corp. Reports Third Quarter 2023 Results

North European Oil Royalty Trust's (NYSE:NRT) earnings growth rate lags the 54% CAGR delivered to shareholders
ITRM

Simply Wall St.

a year ago

North European Oil Royalty Trust's (NYSE:NRT) earnings growth rate lags the 54% CAGR delivered to shareholders

Share on Social Networks: